Tandem Diabetes Care Inc (FRA:TD5A)
€ 46.5 -0.61 (-1.29%) Market Cap: 3.09 Bil Enterprise Value: 3.10 Bil PE Ratio: 0 PB Ratio: 13.74 GF Score: 78/100

Tandem Diabetes Care Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 13, 2020 / 07:00PM GMT
Release Date Price: €80.98 (-4.41%)
Travis Lee Steed
BofA Merrill Lynch, Research Division - VP

Good afternoon, everybody. This is Travis Steed at Bank of America. And up next, we are pleased to have Tandem. We have John Sheridan, President and CEO; Leigh Vosseller, CFO; and Susan Morrison, Executive Vice President and Chief Administrative Officer. Welcome to our virtual Vegas. Hopefully, next year, we can be in person. Just wanted to start out.

Control-IQ got off to a really strong start. COVID hit kind of late in the quarter. And you've got one strong positive tailwind and a strong negative headwind. Just trying to see how balance those 2 dynamics playing out here in April, early May and over the course of the year?

John F. Sheridan
Tandem Diabetes Care, Inc. - President, CEO & Director

Sure. Well, we were -- I think it was fortunate that we were able to get approval in December and actually commercialize the product in the January time frame. It enabled us to train probably 7,000 physicians in the use of Control-IQ. So that was just very fortunate timing. And as you've seen, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot